The Food and Drug Administration (FDA) said it is actively overseeing and validating the voluntary recall initiated by Nestlé Philippines involving specific batches of NAN OPTIPRO and NANKID OPTIPRO infant formula products, citing a precautionary safety and quality concern.
The recall stems from a reported issue involving a raw material supplied to the manufacturer.
The FDA clarified that there are currently no established food safety or regulatory limits for the raw material identified, but an investigation is ongoing to determine the scope of the issue and assess any potential risks.
Working closely with Nestlé Philippines, the FDA is verifying the affected batch numbers and ensuring the swift and complete removal of recalled products from both physical stores and online retail platforms.
The agency is also conducting distribution and communication checks to confirm that recall protocols are being properly implemented across the supply chain.
The FDA emphasized that, as of now, it has not received any reports of illness or adverse events linked to the recalled products. Despite the absence of reported cases, the agency said it supports the precautionary recall, underscoring the need to protect public health, particularly infants and young children.
Consumers are advised to carefully check product batch numbers, immediately stop using any
